Recent performance and context for Moderna (MRNA)

Moderna (MRNA) has drawn fresh investor attention after a mixed stretch for the stock, with the price at US$46.88 and returns up 75.19% over the past year but down over the past 3 months.

The company reports annual revenue of US$2.23b and a net loss of US$3.19b, alongside annual revenue growth of 23.58% and net income growth of 53.10%. These figures provide context for how investors evaluate the stock’s recent performance and future prospects.

Moderna’s share price return has risen strongly over the past year, but the 3 year and 5 year total shareholder returns remain sharply negative. This suggests that recent momentum is rebuilding after a prolonged slump as investors reassess growth potential and risks.

If you are comparing Moderna with other opportunities in healthcare and AI, this is a good moment to scan a curated list of 34 healthcare AI stocks

With Moderna shares up 75.19% over the past year, but still carrying a recent quarterly pullback and ongoing losses of US$3.19b, the key question is simple: is there genuine value here, or is the market already pricing in future growth?

Most Popular Narrative: 73.2% Undervalued

At a last close of US$46.88, the most followed narrative on Moderna sets a fair value of US$175.00, framing the current price as a steep discount according to woodworthfund.

Despite the defunding of US governmental research and health services, Moderna remains in a commanding fundamental position. The company that made its name during the COVID-19 pandemic developing and manufacturing vaccines for the disease at breakneck pace also happened to have bagged a historic windfall in exchange for its performance.

Curious what justifies that gap between price and fair value? The narrative focuses on how past cash inflows, margin assumptions and future revenue trajectories interact.

Result: Fair Value of US$175.00 (UNDERVALUED)

However, this hinges on early pipeline results and regulatory approvals arriving as hoped. Any clinical setbacks or delays could quickly weaken the undervalued argument.

Another angle on valuation

The user narrative leans heavily on fair value of $175.00, but the current P/S of 8.4x tells a tougher story. It is richer than the peer average of 5.3x and far above the fair ratio of 1.5x, which points to meaningful valuation risk if expectations fade.

For a closer look at how this pricing gap compares with peers, it helps to see what the numbers suggest about today’s market expectations. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly divided, this is a moment to look at the figures yourself and move quickly while attention is high. To see exactly what investors are optimistic about in the current setup, review the 1 key reward

Looking for more investment ideas?

If you stop with just one stock, you risk missing opportunities that better match your goals, so use the screener to quickly surface focused, data-backed ideas.

• Target potential bargains by scanning a curated mix of quality and value using the 48 high quality undervalued stocks
• Strengthen your portfolio’s foundation by hunting for companies with healthy finances through the solid balance sheet and fundamentals stocks screener (46 results)
• Spot early opportunities before they hit the mainstream by checking the screener containing 21 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.